EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world safety profile of spesolimab in generalized pustular psoriasis: expanded access programmes in Japan, China and Argentina

Akimichi Morita iD, Min Zheng, Furen Zhang iD, Yu-Ling Shi iD, Xiaoming Liu, Aie Xu, Qianjin Lu iD, Keiichi Yamanaka, Yayoi Tada, Yuichiro Tsunemi, María Laura Galimberti, María Lapadula und 6 weitere

British Journal of Dermatology · 06.09.2026

DOI: 10.1093/bjd/ljag338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 06.09.2026. Verfasst von Akimichi Morita und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, LEO Pharma A/S.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prior to the approval of spesolimab as the first treatment for generalized pustular psoriasis (GPP), it was made available to patients via expanded access programmes in Japan, China and Argentina. As a secondary objective, the safety and tolerability of spesolimab was evaluated in a real-world population of patients with GPP.

Autor:innen und Institutionen

  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Dermatology, The Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China.
  • Dermatology Hospital of Shandong First Medical University & Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
  • Shandong Provincial Key Laboratory of Dermatology and Venereology, Jinan, Shandong, China.
  • Department of Dermatology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Institute of Psoriasis, School of Medicine, Tongji University, Shanghai, China.

ORCID-Profile: Akimichi Morita, Furen Zhang, Yu-Ling Shi, Qianjin Lu, Xinghua Gao

Förderung

  • Boehringer Ingelheim
  • LEO Pharma A/S

Zitieren

APA

Morita, A., Zheng, M., Zhang, F., Shi, Y. L., Liu, X., Xu, A., Lu, Q., Yamanaka, K., Tada, Y., Tsunemi, Y., Galimberti, M. L., Lapadula, M., Veira, R., Pillai, N., Sani Simoes, R., Ding, X., Pöntynen, N., & Gao, X. (2026). Real-world safety profile of spesolimab in generalized pustular psoriasis: expanded access programmes in Japan, China and Argentina. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag338

Vancouver

Morita A, Zheng M, Zhang F, Shi YL, Liu X, Xu A, et al. Real-world safety profile of spesolimab in generalized pustular psoriasis: expanded access programmes in Japan, China and Argentina. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag338

BibTeX
@article{Morita2026,
  author = {Morita, Akimichi and Zheng, Min and Zhang, Furen and Shi, Yu-Ling and Liu, Xiaoming and Xu, Aie and Lu, Qianjin and Yamanaka, Keiichi and Tada, Yayoi and Tsunemi, Yuichiro and Galimberti, María Laura and Lapadula, María and Veira, Rosana and Pillai, Nichiren and Sani Simoes, Rafael and Ding, Xuemei and Pöntynen, Nora and Gao, Xinghua},
  title = {Real-world safety profile of spesolimab in generalized pustular psoriasis: expanded access programmes in Japan, China and Argentina},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljag338}
}
Kostenlos starten →